Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Baxter
AstraZeneca
Merck
Mallinckrodt

Last Updated: November 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Bivalirudin In 0.9% Sodium Chloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00043277 Study Of Angiomax In Infants Under Six Months With Thrombosis Completed The Medicines Company Phase 2 2002-08-01 The goals of this study are: 1. To assess the safety of bivalirudin in infants under six months with arterial or venous thrombosis; 2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as measured by the activated clotting time (ACT) or activated partial thromboplastin time (aPTT) in Infants Under Six Months with arterial or venous thrombosis; 3. To determine the outcome of patients on bivalirudin with respect to thrombus resolution and bleeding complications compared to patients on unfractionated heparin (UH) or low molecular weight heparin (LMWH).
NCT00043940 Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning) Completed The Medicines Company Phase 3 1999-04-01 Primary Objective: To assess the safety of bivalirudin as an alternative anticoagulant therapy for patients with new or previous heparin-induced thrombocytopenia (HIT) / heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) undergoing percutaneous coronary intervention (PCI). This will be measured by the composite incidence of major bleeding events during administration or within 48 hours after stopping bivalirudin (or at hospital discharge, whichever occurs first). The components of the composite endpoint are: a) intracranial bleeding; b) retroperitoneal bleeding; c) bleeding that results in hemodynamic compromise; d) bleeding that requires transfusion of three or more units of whole blood or packed red cells; and e) a decrease in hemoglobin of greater than or equal to g/dL or in hematocrit of greater than or equal to 9%. Secondary Objectives: Each component of the primary composite endpoint. To evaluate the level of anticoagulation achieved with bivalirudin. The goal is to achieve an activated clotting time (ACT) between 300 and 350 sec during PCI and 4-hour bivalirudin infusion. To evaluate bivalirudin's effects on platelet counts.
NCT00073593 Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB Completed The Medicines Company Phase 3 2003-08-01 The purpose of this study is to examine the safety and efficacy of Angiomax as an alternative anticoagulant to heparin with protamine reversal in patients undergoing off-pump coronary artery bypass graft surgery.
NCT00079508 Angiomax in Patients With HIT/HITTS Type II Undergoing CPB Completed The Medicines Company Phase 3 2004-04-01 The purpose of this study is to demonstrate that in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) Type II undergoing cardiac surgery on cardiopulmonary bypass (CPB), Angiomax is a safe and effective anticoagulant.
NCT00079586 Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB) Completed The Medicines Company Phase 3 2004-04-01 The purpose of this study is to demonstrate that in patients undergoing coronary artery bypass grafting (CABG) or CABG-Valve, or Isolated Cardiac Valve surgery on CPB (cardiac surgery), Angiomax is a safe and effective alternative anticoagulant to heparin with protamine reversal.
NCT00093158 Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS) Completed The Medicines Company Phase 3 2003-08-01 The purpose of this study is to show that, when compared with heparin (enoxaparin or unfractionated heparin) and routine GPIIb/IIIa inhibition (either started upfront or at the time of percutaneous coronary intervention [PCI]; Arm A): 1. Bivalirudin with routine GPIIb/IIIa inhibition (either started upfront or at the time of PCI; Arm B) provides non-inferior or superior overall clinical outcomes and 2. Bivalirudin alone (Arm C) reduces clinically significant bleeding. An important secondary objective for this comparison is to show that bivalirudin is not inferior for ischemic complications.
NCT00093184 Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI Completed The Medicines Company Phase 3 2004-04-01 The purpose of this study is to demonstrate the benefit of bivalirudin in combination with clopidogrel with provisional GPIIb/IIIa inhibitor use, in reducing the bleeding complications associated with early invasive management of patients presenting with an ST Elevation Myocardial Infarction (STEMI) and undergoing primary PCI, while providing similar rates of ischemic events when compared to published results of relevant trials.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Bivalirudin In 0.9% Sodium Chloride

Condition Name

Condition Name for Bivalirudin In 0.9% Sodium Chloride
Intervention Trials
Coronary Artery Disease 10
Myocardial Infarction 7
Acute Coronary Syndrome 6
Percutaneous Coronary Intervention 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Bivalirudin In 0.9% Sodium Chloride
Intervention Trials
Myocardial Infarction 20
Infarction 19
Coronary Disease 17
Coronary Artery Disease 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Bivalirudin In 0.9% Sodium Chloride

Trials by Country

Trials by Country for Bivalirudin In 0.9% Sodium Chloride
Location Trials
United States 62
China 29
Italy 11
Germany 10
Netherlands 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Bivalirudin In 0.9% Sodium Chloride
Location Trials
New York 6
North Carolina 6
Ohio 5
Maryland 4
California 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Bivalirudin In 0.9% Sodium Chloride

Clinical Trial Phase

Clinical Trial Phase for Bivalirudin In 0.9% Sodium Chloride
Clinical Trial Phase Trials
Phase 4 31
Phase 3 19
Phase 2 4
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Bivalirudin In 0.9% Sodium Chloride
Clinical Trial Phase Trials
Completed 32
Recruiting 7
Not yet recruiting 7
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Bivalirudin In 0.9% Sodium Chloride

Sponsor Name

Sponsor Name for Bivalirudin In 0.9% Sodium Chloride
Sponsor Trials
The Medicines Company 14
Deutsches Herzzentrum Muenchen 6
AstraZeneca 4
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Bivalirudin In 0.9% Sodium Chloride
Sponsor Trials
Other 63
Industry 28
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Dow
Boehringer Ingelheim
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.